Drug Makers Struggle to Establish ICH Q9 Risk Management Programs
This article was originally published in The Gold Sheet
Executive Summary
Shelves laden with forgotten risk assessments? As drug makers assess quality risks to comply with ICH Q9, they are finding it difficult to integrate their assessments with their quality systems, which is the key to acting on their findings. Such a quality risk management (QRM) program can require tracking systems that span the globe and encompass the whole lifecycle of drug products. Benefits can include better control, quicker approval of changes, clarity about residual risks. Genentech's approach to "operationalizing" risk assessment is described. Hospira warning letter resulted from failure to update risk assessment. Key elements of a QRM program are presented.
You may also be interested in...
Quality Risk Management Adoption More Wide Than Deep – Survey
A high percentage of pharmaceutical companies say they have the quality risk management programs in their manufacturing facilities that US and EU inspectors are asking for. But many of them are not yet very mature.
Quality Risk Management Adoption Wider than it is Deep, Survey Shows
A high percentage of pharmaceutical companies say they have the quality risk management programs that US and EU inspectors are asking for. The trouble is that many of them are not yet very mature.
Roche Builds Quality Risk Management Program in Response to Viracept Crisis
Roche's QRM program forged in crisis after Viracept recalled from AIDS epidemic in Africa due to GMP snafu. Upper management promised EU regulators a global review, called QuaSar. Massive effort involved training thousands of workers on how to assess risks and performing 100,000 FMEA risk assessments in just the first year. How Roche addressed the risks identified, replacing machines and even whole facilities when deemed necessary. How Roche transitioned to the proactive post-crisis second phase of its QRM program. The problem with doing FMEAs on Excel spreadsheets.